- InterView
- ‘Ireland, a bridgehead for companies entering the EU mkt'
- by Nho, Byung Chul Jul 10, 2024 05:48am
- "Ireland has the best condition for multinational pharmaceutical and biotech companies to invest and operate in as a bridgehead to the European market." Rory Mullen, Global Head of Biopharma and Food at Investment Promotion & Development Agency Ireland explained so during his recent visit to South Korea. Mr. Mullen visited Korea to discus
- InterView
- “Prolia demonstrated a long-term treatment effect"
- by Son, Hyung-Min Jul 5, 2024 05:49am
- “Prolia has consistently been proven to increase bone density based on clinical trials conducted over 10 years. Patients prescribed with Prolia have demonstrated such. Based on this evidence we hope that Prolia’s preventative effect on bone fracture becomes known in South Korea.“ During a recent meeting with Daily Pharm, David Dempster,
- InterView
- ‘Leqembi enables prevention of Alzheimer's disease’
- by Son, Hyung-Min Jun 27, 2024 05:47am
- "Now that there is a treatment for Alzheimer's disease, we can prevent dementia by 90% if it is detected early. With better drugs expected to be developed in the future, we should provide timely treatment for the patients so they can live to grasp that new opportunity." Duk Lyul Na, Director of the Happymind Clinic (former Professor of Ne
- InterView
- 1 year after Lynparza approved for early-stage breast cancer
- by Son, Hyung-Min May 7, 2024 05:50am
- It’s been over a year since Lynparza was approved for the treatment of early-stage breast cancer. Previously, Lynparza was mainly used for treating metastatic breast cancer, but it expanded its usage following the approval last year for the early-stage treatment. As Lynparza has been confirmed to have a superior drug tolerance in the real
- InterView
- 'BMS will invest in and improve access to new drugs in KOR'
- by Eo, Yun-Ho Apr 15, 2024 06:06am
- Multinational pharmaceutical companies are masters of adaptation and transformation. They adjust their pipelines and introduce new drugs through various mergers and acquisitions and technology export agreements to meet the rapidly changing trends in the healthcare industry. This involves a great deal of foresight. The companies need to as
- InterView
- ‘New head, new drugs…Bayer’s transition has just begun'
- by Eo, Yun-Ho Mar 25, 2024 05:59am
- Everyone gets stuck at some point. The difference is in how quickly you resolve the situation and carry on. The multinational pharmaceutical giant Bayer Korea was certainly ‘stuck’ at one point. Although the company had released and successfully sold liver cancer treatments ‘Nexavar’ and ‘Stivarga,’ the anticoagulant ‘Xarelto,’ a
- InterView
- “Solid position of JAK inhibitors despite ongoing concerns"
- by Eo, Yun-Ho Mar 15, 2024 05:48am
- JAK inhibitors, an 'oral drug' that initially gained attention in the field of autoimmune diseases, are now considered one of the treatment options. The first approved ‘Xeljanz (tofacitinib)’ has accumulated a ten-year prescription record. The fifth JAK inhibitor, ‘Jyseleca (filgotinib),’ is now available on the reimbursement listin
- InterView
- ‘Yuhan expects Leclaza’s FDA approval this year'
- by Kim, Jin-Gu Feb 5, 2024 05:52am
- Wook-Je Cho (59), President, CEO & Executive Director of Yuhan Corp, has set global commercialization of its new anti-cancer drug Leclaza (lazertinib) as the company’s top priority this year. Last year, the company focused on the challenge of securing first-line reimbursement coverage for Leclaza in Korea. This year, he plans to move on to t
- InterView
- Patent outlook after Forxiga withdrawal in Korea
- by Kim, Jin-Gu Jan 24, 2024 12:37pm
- If ‘Forxiga (dapagliflozin)’, a SGLT-2 inhibitor class treatment for diabetes, is withdrawn from the Korean market, the question is whether companies can begin selling generics containing the same active ingredient for the treatment of heart failure. The answer to the question is that selling Forxiga generics for the purpose of treati
- InterView
- ‘2nd line opt for CMV is limited…should improve access'
- by Son, Hyung-Min Jan 15, 2024 05:36am
- An expert had suggested that we improve access to a new cytomegalovirus (CMV) treatment drug that has shown effect in patients with resistance as CMV has a major impact on transplanted organs. Sung Shin, Professor of Kidney and Pancreas Transplantation at Asan Medical Center (Director of General Affairs, the Korean Society for Transplanta
